Alnylam Pharmaceuticals
$231.18Change from previous close: −6.31%Absolute change: −$15.56
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $30.93B
- Enterprise value
- $30.61B
- P/E (trailing 12 months)
- 42.9
- Forward P/E
- 18.5
- PEG
- 0.32
- Price/book
- 22.8
- Price/sales
- 6.44
- EV/EBITDA
- 29.0
- EV/revenue
- 6.37
Profitability and growth
- Gross margin
- 79.7%
- Operating margin
- 17.9%
- Net margin
- 16.1%
- ROE
- 96.6%
- ROA
- 12.3%
- Revenue growth (year over year)
- 66.9%
Financial health
- Total cash
- $3.31B
- Total debt
- $2.99B
- Debt/equity
- 2.21
- Current ratio
- 3.06
- Quick ratio
- 2.79
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $371.12
- Median price target
- $350.00
- High price target
- $536.00
- Low price target
- $256.00
- Analysts with a price target
- 26
- Consensus
- Buy
- Forward EPS
- $12.47
- EPS estimate, current year
- $8.83
Shares and trading
- Beta
- 0.30
- Average volume
- 1.83M
- Shares outstanding
- 133.81M
- Float
- 133.24M
- Institutional ownership
- 101.8%
- Insider ownership
- 0.2%
- Short interest (% of float)
- 7.2%
- Short ratio (days)
- 4.19